Lilly names David Ricks as new US affiliate leader; Eric Baclet to head up China business
US drug major Eli Lilly says that David Ricks, currently general manager of Lilly China, has been promoted to president, Lilly USA. Mr Ricks will succeed Enrique Conterno, who was named leader of Lilly's new Diabetes Business Unit as part of a company reorganization announced September 14.
Mr Ricks, a 13-year Lilly veteran, worked in the US affiliate for several years from 1998 to 2002 as a marketing manager and then as a district sales manager. Most recently, he served as general manager of Lilly Canada from 2005 to 2008, and as general manager of China since July 2008.
He will report directly to Bryce Carmine, recently named head of Lilly's Established Markets Business Unit, and will assume his new role beginning November 1. Eric Baclet, currently vice president of marketing over global neuroscience brands, will succeed Mr Ricks to lead Lilly China
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze